About Us

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company’s lead clinical-stage asset, TH104, has been observed to suppress chronic, debilitating pruritus or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure. The Company’s early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company’s antibody discovery technology platform against these and other specified targets.

Executive Management

6adea952161541d54c74110a037c0776@2x
c0f666a763d932a09217e83ff47e0165
cfedf49a4a13bc3aa576ed14b1af3ef6
Nir Barak new
Loading...

Board of Directors

Loading...

Scientific Advisory Board

Loading...